uniQure Faces Securities Fraud Lawsuit After FDA Setback

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: 13 hours ago

0mins

QURE-32.82%

Should l Buy QURE?

Source: Globenewswire

Stock Price Plunge: uniQure N.V. shares fell over 35% on March 2, 2026, following the FDA's negative feedback on its AMT-130 gene therapy clinical data, which not only undermines investor confidence but may also affect the company's future financing capabilities.
Lawsuit Initiation: A securities class action has been filed against uniQure and certain executives for misleading investors about the strength of clinical results and regulatory prospects between September 24 and October 31, 2025, highlighting significant deficiencies in the company's information disclosure practices.
Historical Stock Volatility: On November 3, 2025, uniQure's stock price had previously dropped by 66% due to FDA feedback regarding inadequate clinical data, indicating ongoing challenges in regulatory compliance that could impact its market position.
Investor Action Recommendation: Investors are advised to contact Block & Leviton by April 13, 2026, to seek appointment as lead plaintiff; those who take no action will be considered absent class members and may lose their opportunity for recovery.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy QURE?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on QURE

Wall Street analysts forecast QURE stock price to rise

10 Analyst Rating

8 Buy

2 Hold

0 Sell

Strong Buy

Current: 15.630

Low

33.00

Averages

49.88

High

70.00

Current: 15.630

Low

33.00

Averages

49.88

High

70.00

Stifel

maintain

2026-02-26

New

Reason

Stifel

Price Target

AI Analysis

2026-02-26

New

maintain

Reason

Stifel says that it can see why uniQure's (QURE) shares are lower on CNBC comments from FDA commissioner Marty Makary, where he was interviewed about FDA's approach to rare disease. Makary was defensive of FDA's approach broadly, as he appeared to maybe refer to the AMT-130 program as an example of something his FDA didn't get behind. To be clear, his specific commentary might/might not have been referring to AMT-130 since uniQure never received an actual CRL, the firm notes. Some seem to think Makary was referring to Regenxbio's (RGNX) RGX-121, but this doesn't really make sense to Stifel since he describes a drug that didn't beat a control arm, and the Regenxbio study in Hunter was single-arm. Specific details aside, what's also notable is his steadfast defense of FDA which is discouraging for those hoping that the agency can be convinced to reconsider recent negative decisions, in the absence of specific political pressure, argues the firm.

RBC Capital

Outperform

maintain

$45

2026-02-26

New

Reason

RBC Capital

Price Target

$45

2026-02-26

New

maintain

Outperform

Reason

RBC Capital reiterated an Outperform rating and $45 price target on uniQure shares after the stock is trading down following FDA Commissioner Marty Makary's CNBC appearance on rare disease therapy approvals. While the company was not mentioned by name, the Commissioner's comments referencing researchers drilling holes in patients' skulls appear directed at uniQure's gene therapy approach for Huntington's Disease, the firm told investors in a research note. RBC added that while the news is "disappointing", it is yet to hear a formal announcement from the company.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for QURE

Unlock Now

About QURE

Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

uniQure Reports 2025 Financial Results and Clinical Progress

21 hours agoNewsfilter

AMT-130 Progress: In September 2025, uniQure reported that AMT-130 clinical trial data showed a significant 75% slowing of disease progression in patients receiving high-dose treatment, offering hope for a potential first disease-modifying therapy for Huntington's disease patients.
FDA Meeting Outcome: Following a Type A meeting with the FDA, the agency indicated that existing data are insufficient to support a marketing application for AMT-130 and recommended a prospective randomized controlled study; uniQure plans to request a Type B meeting in Q2 2026 to discuss further development.
Improved Financial Position: As of December 31, 2025, uniQure reported cash and cash equivalents of $622.5 million, expected to fund operations into the second half of 2029, demonstrating strong financial management.
Clinical Trial Updates: In 2026, uniQure will release updated clinical data for AMT-260 and AMT-191, with the former showing a 92% reduction in seizure frequency for refractory temporal lobe epilepsy and the latter demonstrating significant increases in α-Gal A enzyme activity in Fabry disease patients, further solidifying its leadership in gene therapy.

Mixed Close for US Stocks Amid Iran War Impact

9 hours agoNASDAQ.COM

Mixed Market Performance: On Monday, the S&P 500 closed up 0.04%, while the Dow Jones Industrial Average fell 0.15%, and the Nasdaq 100 rose 0.13%, reflecting a divergence in market sentiment influenced by the ongoing war in Iran, with increased demand for defense and energy stocks.
Surge in Oil Prices: WTI crude oil prices soared over 6% to an 8.25-month high following Iran's attack on oil tankers, which is expected to elevate inflation expectations and impact the overall economic environment and investor confidence.
Strong Manufacturing Index: The US February ISM manufacturing index unexpectedly rose to 52.4, surpassing the market expectation of 51.5, indicating economic resilience that could influence the Federal Reserve's monetary policy direction, leading to shifts in future rate hike expectations.
Optimistic Earnings Outlook: More than 90% of S&P 500 companies have reported earnings, with 73% exceeding expectations, and Q4 earnings growth is projected at 8.4%, providing market support despite geopolitical risks.

uniQure Faces Setback in FDA Approval for AMT-130

11 hours agoseekingalpha

FDA Feedback: uniQure's hopes for a fast approval of its Huntington's disease candidate AMT-130 were dashed as the FDA mandated a Phase 3 randomized, double-blind, sham surgery-controlled study, resulting in a ~33% drop in stock price on Monday, indicating diminished market confidence in its clinical pathway.
Clinical Data Analysis: Despite the company reporting a 75% slowing of disease progression and a 60% reduction in total functional capacity from its Phase 1/2 study, the FDA deemed the existing data insufficient to support a BLA submission, reflecting the agency's stringent requirements for data quality.
Next Steps: uniQure plans to request a Type B meeting with the FDA in Q2 to discuss future strategies, indicating the company's intent to explore approval possibilities through further dialogue, despite facing significant challenges.
Market Reaction: CEO Matthew Kapusta acknowledged during a conference call that the FDA had conveyed in an October pre-BLA meeting that the submitted data was unlikely to support a BLA submission, highlighting the difficulties the company faces in communicating with regulators, which may impact investor confidence.

uniQure Q4 2025 Earnings Call Insights

11 hours agoseekingalpha

Gene Therapy Progress: uniQure's Q4 2025 earnings call highlighted groundbreaking three-year data for AMT-130, showing a 75% slowing of disease progression in Huntington's disease; however, the FDA indicated that the data may not support a BLA submission, creating regulatory uncertainty.
Financial Performance: Revenue for 2025 was $16.1 million, down from $27.1 million in 2024, primarily due to decreased collaboration and contract manufacturing revenues, indicating challenges in diversifying income streams.
Increased R&D Expenses: Research and development expenses reached $140.7 million, a $19.4 million increase year-over-year, mainly for AMT-130 BLA submission preparations, reflecting the company's significant investment and associated risks in advancing critical projects.
Future Outlook: Management plans to request a Type B meeting in Q2 2026 to discuss Phase III design options; despite regulatory challenges, uniQure remains committed to advancing its gene therapies and clinical development efforts.